Serenex and CHDI, Inc. Form Agreement to Evaluate Proprietary Small Molecule Hsp90 Inhibitors as a Potential Treatment for Huntington's Disease

DURHAM, NC--(Marketwire - January 17, 2008) - Serenex, Inc., a leader in the discovery and development of small molecule Heat Shock Protein 90 (Hsp90) inhibitors, and CHDI, Inc., a non-profit organization seeking to rapidly discover and develop drugs that prevent or slow Huntington's disease (HD), today announced that they have entered into an agreement under which CHDI will assess a number of Serenex's novel, small molecule, brain penetrating and orally bioavailable Hsp90 inhibitors as potential therapeutics for Huntington's disease. Under the terms of the agreement, Serenex will retain all rights to develop and commercialize evaluated molecules. The Hsp90 inhibitors being tested are synthetic small molecules discovered internally using Serenex's proprietary chemoproteomics technology platform.

Back to news